BRPI0713730A2 - combinações compreendendo estaurosporinas - Google Patents

combinações compreendendo estaurosporinas Download PDF

Info

Publication number
BRPI0713730A2
BRPI0713730A2 BRPI0713730-3A BRPI0713730A BRPI0713730A2 BR PI0713730 A2 BRPI0713730 A2 BR PI0713730A2 BR PI0713730 A BRPI0713730 A BR PI0713730A BR PI0713730 A2 BRPI0713730 A2 BR PI0713730A2
Authority
BR
Brazil
Prior art keywords
mcl
formula
typically
lower alkyl
phenyl
Prior art date
Application number
BRPI0713730-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Peter Valent
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0713730A2 publication Critical patent/BRPI0713730A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0713730-3A 2006-06-23 2007-06-22 combinações compreendendo estaurosporinas BRPI0713730A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0612542.1A GB0612542D0 (en) 2006-06-23 2006-06-23 Combinations comprising staurosporines
GB0612542.1 2006-06-23
PCT/EP2007/005517 WO2007147613A2 (en) 2006-06-23 2007-06-22 Combinations comprising staurosprorines

Publications (1)

Publication Number Publication Date
BRPI0713730A2 true BRPI0713730A2 (pt) 2012-10-30

Family

ID=36803826

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713730-3A BRPI0713730A2 (pt) 2006-06-23 2007-06-22 combinações compreendendo estaurosporinas

Country Status (12)

Country Link
US (1) US20100184820A1 (enExample)
EP (1) EP2037933A2 (enExample)
JP (1) JP2009541240A (enExample)
KR (1) KR20090033874A (enExample)
CN (1) CN101505760A (enExample)
AU (1) AU2007263278A1 (enExample)
BR (1) BRPI0713730A2 (enExample)
CA (1) CA2655724A1 (enExample)
GB (1) GB0612542D0 (enExample)
MX (1) MX2008016488A (enExample)
RU (1) RU2009101972A (enExample)
WO (1) WO2007147613A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143578A1 (en) * 2008-05-28 2009-12-03 The Council Of The Queensland Institute Of Medical Research Cancer drug target and methods of diagnosis and therapy
CN102101866A (zh) * 2010-11-04 2011-06-22 中国海洋大学 十字孢碱卤代衍生物及其制备方法和应用
FI20115640A0 (fi) * 2011-06-22 2011-06-22 Turun Yliopisto Yhdistelmähoito
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
CN104619845A (zh) 2012-07-13 2015-05-13 图尔库大学 联合治疗iii
CN110218206B (zh) * 2016-06-01 2022-03-04 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN106146475B (zh) * 2016-06-01 2019-05-17 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
SG10201607303YA (en) 2016-09-01 2018-04-27 Agency Science Tech & Res Antisense oligonucleotides to induce exon skipping
WO2019000224A1 (zh) * 2017-06-27 2019-01-03 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN107569491A (zh) * 2017-08-30 2018-01-12 杭州科兴生物化工有限公司 一种星孢菌素类化合物的应用
EP4351564A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
CN114437109B (zh) * 2022-03-08 2023-09-29 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种十字孢碱卤代衍生物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001992A (en) * 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US7973031B2 (en) * 2001-10-30 2011-07-05 Novartis Ag Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
CA2533861A1 (en) * 2003-08-08 2005-02-17 Novartis Ag Combinations comprising staurosporines

Also Published As

Publication number Publication date
WO2007147613A3 (en) 2008-07-03
EP2037933A2 (en) 2009-03-25
CN101505760A (zh) 2009-08-12
KR20090033874A (ko) 2009-04-06
AU2007263278A1 (en) 2007-12-27
WO2007147613A2 (en) 2007-12-27
MX2008016488A (es) 2009-01-22
RU2009101972A (ru) 2010-07-27
JP2009541240A (ja) 2009-11-26
US20100184820A1 (en) 2010-07-22
CA2655724A1 (en) 2007-12-27
GB0612542D0 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
BRPI0713730A2 (pt) combinações compreendendo estaurosporinas
ES2269793T3 (es) Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3.
US11179412B2 (en) Methods of treating conditions involving elevated inflammatory response
CN113924365A (zh) 用于治疗kras相关疾病或病症的组合物和方法
EP3432886B1 (en) Pim kinase inhibitors in combination with rna splicing modulators/inhibitors for treatment of cancers
US20130289018A1 (en) New Use of Staurosporine Derivatives
Zhang et al. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis
US20240408091A1 (en) Compositions and methods for treating vascular ehlers danlos syndrome and associated disorders
US11696924B2 (en) Combination therapy using PDK1 and PI3K inhibitors
Oh et al. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells
US8748428B2 (en) Use of a PKC inhibitor
WO2020239685A1 (en) Combinations of therapeutic agents for treating uveal melanoma
US20090169540A1 (en) Use Of An Antagonist Of Epac For Treating Human Cardiac Hypertrophy
US20250082652A1 (en) Signalling-pathway inhibitor combinations for use in the treatment of cancer diseases
US20210189399A1 (en) Use of mir-223-3p as a cancer therapeutic and method for treating cancer using the same
da Silva Fernandes The Role of Inosine Monophosphate Dehydrogenase 2 (IMPDH2) in the Chemoresistance of Triple Negative Breast Cancer
Howard Characterization of the CXCR4-LASP1-eIF4F Axis in Triple-Negative Breast Cancer
WO2017160797A1 (en) Combination therapy with c-myc nucleic acid inhibitors and selective cdk7 inhibitors
JP2023010407A (ja) 子宮肉腫を予防及び/又は治療するための医薬組成物
Lung Transient PI3K Inhibition Induces Apoptosis and Overcomes
JPWO2020040185A1 (ja) Hsp47の阻害物質を用いた、化学療法剤感受性の増強
Ujiki et al. Involvement of P21/WAF1 and cyclin E in induction of pancreatic cancer cell G0/G1 arrest and apoptosis by a novel peptide sansalvamide analogue
Lancet Farnesyl Transferase Inhibitors in the Therapy of AML
HK1095519B (en) The use of staurosporine derivatives for the manufacture of a medicament
AU2008201870A1 (en) New pharmaceutical uses of Staurosporine derivatives

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.